What Is LL-37? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. LL-37 is not FDA-approved for human therapeutic use. Products sold online as LL-37, cathelicidin LL-37, antimicrobial peptide LL-37, injectable LL-37, topical LL-37, nasal LL-37, or “research use only” LL-37 may carry safety, quality, legal, and regulatory risks.

Quick answer

LL-37 is the only human cathelicidin antimicrobial peptide. It is a 37-amino-acid host-defense peptide produced from the precursor protein hCAP18. LL-37 is studied for antimicrobial activity, antibiofilm effects, immune modulation, inflammation, wound healing, epithelial barrier defense, and tissue repair. It can act against bacteria, fungi, viruses, and biofilms in experimental systems, and it also affects immune-cell signaling, inflammation, angiogenesis, and wound repair. However, LL-37 is not FDA-approved, human therapeutic evidence remains limited, and FDA says compounded drugs containing cathelicidin LL-37 may pose immunogenicity risk and peptide-characterization concerns. Online claims that LL-37 treats infections, Lyme disease, long COVID, wounds, immune dysfunction, or anti-aging are not established by strong human clinical trials.

Key facts about LL-37

What is LL-37?

LL-37 is a human antimicrobial peptide from the cathelicidin family. In humans, the cathelicidin precursor protein is called hCAP18. When processed, it releases LL-37, a 37-amino-acid peptide with broad host-defense activity.

LL-37 is called “LL-37” because it begins with two leucine residues, abbreviated LL, and contains 37 amino acids.

A PubMed review titled “Cathelicidin LL-37: a multitask antimicrobial peptide” describes LL-37 as a multifunctional host-defense molecule important for immune responses to infection and tissue injury.

A PMC review on LL-37 as a therapeutic antimicrobial and antibiofilm agent notes that the single human cathelicidin peptide LL-37 has antimicrobial and antibiofilm activity against multiple Gram-positive and Gram-negative bacteria.

The key distinction:

LL-37 is a real human host-defense peptide, but synthetic LL-37 sold online is not an FDA-approved infection treatment, immune therapy, wound-healing drug, or anti-aging peptide.

How does LL-37 work?

LL-37 has multiple biological roles.

Research discusses LL-37 in relation to:

• Direct antimicrobial activity
• Antibiofilm activity
• Bacterial membrane disruption
• Fungal and viral defense mechanisms
• Immune-cell recruitment
• Cytokine signaling
• Inflammation regulation
• Epithelial barrier function
• Wound healing
• Angiogenesis
• Keratinocyte activity
• Lung and skin innate immunity

In plain English:

LL-37 is part of the body’s innate immune defense system. It can directly interact with microbes and also helps coordinate immune and tissue-repair responses.

But LL-37 is not simply “natural antibiotic.” That framing is too simplistic.

LL-37 can be both protective and potentially inflammatory depending on context. It is involved in normal host defense, but abnormal LL-37 activity has also been discussed in inflammatory skin conditions, autoimmunity, and tissue-damage contexts.

A PubMed review on unique features of human cathelicidin LL-37 describes LL-37 as an antimicrobial peptide able to induce various effects, including both anti-inflammatory and pro-inflammatory activity.

The practical interpretation:

LL-37 is immune-active. That is why it is interesting, but also why unsupervised use is not low-risk.

What is LL-37 used for?

LL-37 is commonly discussed for infections, biofilms, Lyme disease, wound healing, skin health, immune support, gut health, and long COVID. These uses differ sharply in evidence quality.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Antimicrobial activity | Strong preclinical evidence | LL-37 has antimicrobial activity in experimental systems. | It is not an FDA-approved antibiotic or infection treatment. | | Biofilms | Strong preclinical evidence | LL-37 has antibiofilm activity in lab models. | Human biofilm-infection treatment efficacy is not established. | | Wound healing | Moderate preclinical evidence | Topical synthetic and recombinant LL-37 increased vascularization and re-epithelialization in experimental wound models. | Human wound-healing efficacy is not established by large trials. | | Skin barrier and inflammation | Mechanistic / preclinical | LL-37 is involved in skin innate immunity and inflammatory signaling. | It is not approved for eczema, psoriasis, acne, rosacea, or dermatitis. | | Respiratory infection biology | Mechanistic / review-level | LL-37 is studied in lung infection and inflammation contexts. | It is not approved for respiratory infections or viral illnesses. | | Lyme disease | Weak / marketing-driven | Online claims often focus on antimicrobial and biofilm effects. | Human evidence for Lyme disease treatment is lacking. | | Long COVID | Speculative / mechanistic | LL-37 has been discussed in SARS-CoV-2 host-defense biology. | It is not an approved long COVID treatment. | | Immune support | Weak / overbroad | LL-37 is part of innate immunity. | “Immune boosting” claims are not clinically proven and may be unsafe. | | Anti-aging | Unsupported | Host-defense peptides are involved in tissue repair. | No strong evidence supports LL-37 as an anti-aging therapy. | | Online research-use LL-37 | High uncertainty | Sold as injectable, nasal, and topical products. | Quality, sterility, identity, concentration, absorption, and safety may be unknown. |

What does the research show?

Antimicrobial and antibiofilm evidence

LL-37 has substantial preclinical antimicrobial evidence.

A PMC review describes LL-37 as having antimicrobial and antibiofilm activity against multiple Gram-positive and Gram-negative bacteria.

A PubMed review also discusses LL-37 as a potential therapeutic antimicrobial and antibiofilm agent.

This supports a narrow claim:

LL-37 has antimicrobial and antibiofilm activity in experimental systems.

It does not prove that LL-37 injections, sprays, or topical products treat human infections.

Wound-healing evidence

LL-37 has interesting wound-healing research.

A PubMed wound-healing study reported that topical synthetic and recombinant LL-37 increased vascularization and re-epithelialization in experimental wound models.

The practical interpretation:

LL-37 may play a real role in wound-regeneration biology, but it is not an FDA-approved wound-healing medication.

Immune modulation and inflammation evidence

LL-37 is more than an antimicrobial peptide.

A PubMed review describes LL-37 as a host-defense molecule essential for normal immune responses to infection and tissue injury.

A PubMed review on LL-37 and intestinal inflammation describes LL-37 as the sole human cathelicidin and discusses its relationship with inflammatory bowel disease and intestinal inflammatory pathways.

The practical interpretation:

LL-37 has legitimate immunology relevance, but immune relevance does not equal safe immune therapy.

Clinical translation limitations

Despite strong biological interest, clinical use is difficult.

A 2025 PubMed review on cathelicidin antimicrobial peptides notes that clinical application of LL-37 is hindered by limitations including low proteolytic stability, cytotoxicity, and other translational issues.

The practical interpretation:

LL-37 is promising in theory, but difficult to turn into a safe, approved drug.

FDA safety and compounding context

FDA has specifically flagged cathelicidin LL-37 in the compounding-risk context.

The FDA page on certain bulk drug substances that may present significant safety risks states that compounded drugs containing cathelicidin LL-37 may pose immunogenicity risk for certain routes of administration and may have complexities related to peptide impurities and active pharmaceutical ingredient characterization. FDA also says it lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm if administered to humans.

The practical interpretation:

FDA has not treated compounded LL-37 as a routine low-risk peptide. It has specifically identified safety-data and peptide-quality concerns.

Evidence summary

Is LL-37 FDA-approved?

No. LL-37 is not FDA-approved.

There is no FDA-approved LL-37 product for infections, Lyme disease, biofilms, wound healing, immune support, gut inflammation, skin disease, long COVID, anti-aging, or any other therapeutic use.

The FDA states that compounded drugs containing cathelicidin LL-37 may pose immunogenicity risk for certain routes of administration and may have peptide-related impurity and API-characterization challenges. FDA also says it lacks sufficient safety-related information to know whether cathelicidin LL-37 would cause harm if administered to humans.

The key distinction:

LL-37 is a human host-defense peptide with real biology, but it is not an FDA-approved medication.

Is LL-37 legal?

LL-37’s legal status depends on product type, intended use, route, jurisdiction, and how it is sold.

The practical answer is simple:

LL-37 is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.

Some sellers market LL-37 as a research peptide, antimicrobial peptide, Lyme peptide, biofilm peptide, wound-healing peptide, immune peptide, nasal spray, topical, or injectable. That does not make it safe, approved, legal, or appropriate for consumer use.

The blunt version:

Buying “research use only” LL-37 online is not the same as receiving an FDA-approved prescription medication from a legitimate pharmacy.

Is LL-37 banned in sports?

I did not find LL-37 specifically named on the WADA prohibited list in the sources reviewed here.

However, athletes should be careful for several reasons:

1. Peptide products can be contaminated or mislabeled.
2. Anti-doping status can change.
3. Unapproved pharmacologic substances can create risk depending on classification, route, or accompanying ingredients.
4. Online peptide products may contain substances other than what is listed on the label.

The WADA Prohibited List and USADA prohibited-list guidance should be checked directly before use.

The practical advice:

Athletes should verify LL-37 through Global DRO, WADA, or USADA before using it and should avoid unapproved online peptide products.

Safety and side effects

LL-37 should not be treated as risk-free.

Possible or theoretical concerns include:

• Injection-site reactions for injectable products
• Skin irritation for topical products
• Nasal irritation for nasal products
• Immune or allergic reactions
• Immunogenicity risk
• Inflammation dysregulation
• Cytotoxicity concerns
• Unknown long-term safety
• Unknown route-specific safety
• Unknown interaction risk with antibiotics, biologics, immunosuppressants, anti-inflammatory drugs, or immune therapies
• Product-quality and sterility risks from online sources
• Mislabeling or incorrect concentration
• Contamination risk
• Peptide impurity and API-characterization problems

The biggest safety issue is uncertainty.

FDA says it lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm if administered to humans.

A serious evaluation of LL-37 should separate normal endogenous immune biology from injecting or applying synthetic LL-37 products bought online.

LL-37 vs similar peptides and drugs

The key distinction:

LL-37 belongs in the host-defense antimicrobial peptide category. It is not an approved antibiotic, supplement, GLP-1 drug, growth hormone peptide, cosmetic peptide, or general immune booster.

Why is LL-37 sold as “research use only”?

Some online sellers use “research use only” language to sell LL-37 outside normal drug channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate LL-37 claims online

Bottom line

LL-37 is the only human cathelicidin antimicrobial peptide and a major host-defense molecule involved in antimicrobial activity, antibiofilm effects, immune signaling, inflammation, wound healing, and barrier defense. The biology is real and scientifically important.

The most defensible conclusion is:

LL-37 is a promising research peptide, not a proven consumer therapy. It is not FDA-approved, FDA has raised safety and peptide-characterization concerns for compounded cathelicidin LL-37, and online claims about Lyme disease, infections, biofilms, immune support, wound healing, and long COVID often go beyond the current human evidence.

FAQ

What is LL-37?

LL-37 is the only human cathelicidin antimicrobial peptide. It is a 37-amino-acid host-defense peptide produced from the hCAP18 precursor.

What does LL-37 do?

LL-37 is studied for antimicrobial, antibiofilm, immune-modulating, inflammatory, epithelial barrier, and wound-healing effects.

Is LL-37 FDA-approved?

No. LL-37 is not FDA-approved for infection treatment, Lyme disease, wound healing, immune support, long COVID, skin disease, or any other therapeutic use.

Is LL-37 an antibiotic?

No. LL-37 has antimicrobial activity in experimental systems, but it is not an FDA-approved antibiotic.

Does LL-37 kill biofilms?

LL-37 has antibiofilm activity in lab research, but that does not prove it treats human biofilm infections.

Does LL-37 help wound healing?

Preclinical studies suggest LL-37 may support wound-healing processes such as vascularization and re-epithelialization. Human therapeutic evidence is not strong enough for approval-level claims.

Does LL-37 treat Lyme disease?

No strong human clinical evidence establishes LL-37 as a Lyme disease treatment. Lyme-related claims are mostly extrapolated from antimicrobial and biofilm research.

Does LL-37 treat long COVID?

No. LL-37 has been discussed in host-defense and viral biology, but it is not an approved long COVID treatment.

Is LL-37 safe?

LL-37 does not have enough human safety data to call it safe for consumer use. FDA has raised concerns about immunogenicity, peptide impurities, API characterization, and lack of sufficient safety information.

Is LL-37 legal?

LL-37 is not an FDA-approved drug. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.

Is LL-37 banned in sports?

I did not find LL-37 specifically named on the WADA prohibited list in the sources reviewed here. Athletes should verify current status with WADA, USADA, or Global DRO before use.

Why do sellers call LL-37 “research use only”?

Sellers often use “research use only” language because LL-37 is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with LL-37?

The biggest risks are using an unapproved immune-active peptide without adequate human safety data, relying on preclinical antimicrobial evidence instead of human clinical trials, and buying online products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
2. PubMed: Cathelicidin LL-37, a multitask antimicrobial peptide
3. PMC: The Human Cathelicidin Antimicrobial Peptide LL-37 as a Therapeutic Antimicrobial and Antibiofilm Agent
4. PubMed: The Human Cathelicidin Antimicrobial Peptide LL-37 as a Therapeutic Antimicrobial and Antibiofilm Agent
5. PubMed: Wound healing activity of the human antimicrobial peptide LL-37
6. PubMed: Unique Features of Human Cathelicidin LL-37
7. PubMed: LL-37, cathelicidin-related antimicrobial peptide with immunomodulatory activity
8. PubMed: Antimicrobial Peptides of the Cathelicidin Family, Focus on LL-37
9. PMC: Antimicrobial Peptides of the Cathelicidin Family
10. PubMed: The human cathelicidin LL-37, a multifunctional peptide involved in infection and inflammation
11. PubMed: The human antimicrobial peptide LL-37 suppresses keratinocyte apoptosis
12. PubMed: LL-37 inhibits amyloid self-assembly of islet amyloid polypeptide
13. WADA: Prohibited List
14. WADA: 2026 Prohibited List
15. USADA: WADA Prohibited List Guidance